comparemela.com

Latest Breaking News On - Harmony biosciences - Page 6 : comparemela.com

Harmony Biosciences (HRMY) Scheduled to Post Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) is set to announce its earnings results before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. Harmony Biosciences […]

United statesJeffrey dierksHarmony biosciences holdings incHarmony biosciences company profileCantor fitzgeraldSecurities exchange commissionGoldman sachs groupNeedham companyHarmony biosciencesGet free reportExchange commissionBiosciences holdingsHarmony biosciences dailyNasdaq hrmy

Myotonic Dystrophy Pipeline Assessment 2024 | In-Depth Insights Into The Emerging Drugs, Latest FDA Approvals, Clinical Trials, Ter, Key Companies

Myotonic Dystrophy Pipeline Assessment 2024 | In-Depth Insights Into The Emerging Drugs, Latest FDA Approvals, Clinical Trials, Ter, Key Companies
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Nexien biopharmaCompanies in myotonic dystrophy therapeutics marketLocana incRoute of administrationDrug administrationAdministration roPepgen corporationKey companiesSyros pharmaceuticalsDystrophy pipelineMyotonic dystrophy marketHarmony biosciencesAvidity biosciencesDyne therapeuticsEntrada therapeuticsArthex biotech

Harmony Biosciences (NASDAQ:HRMY) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock. Several other research analysts also recently weighed in on HRMY. Bank of America restated an underperform rating and issued […]

United statesJeffrey dierksCharles schwab investment management incCantor fitzgeraldNeedham companyJupiter asset management ltdJanney montgomery scottGoldman sachs groupHarmony biosciences holdings incHarmony biosciencesFree reportModerate buyGet free reportSchwab investment managementCapital partnersForest capital management

Harmony Secures Rights to Develop Bioprojet s Orexin-2 Agonist

Harmony has entered into a licensing agreement to develop and commercialize TPM-1116, a selective oral orexin-2 receptor agonist.

United statesJean charles schwartzJeffreym daynoHarmony biosciences holdings incHarmony biosciencesLatin americanBiosciences holdings incEuropean academies

PR News | Health Firms Post Paltry 2 6% Growth in 23

PR News | Health Firms Post Paltry 2 6% Growth in 23
odwyerpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from odwyerpr.com Daily Mail and Mail on Sunday newspapers.

United statesJennifer oneillRuder finnTom jonesMathew shearmanKristie kuhlGil basheRichard hatzfeldAnna kotisAlex taylorGoel jasperMaryellen royleEvan krausGagen macdonaldChristie anbarMark chataway

vimarsana © 2020. All Rights Reserved.